- Amid the excitement, questions remain over virus mutations, people refusing to take it and the problem of storing it at -80 degrees
- In short, given the general public may face a wait of up to year before getting a shot, it’s worth thinking twice before booking that plane ticket
The coronavirus vaccine developed by Pfizer and BioNTech has raised hopes for the end of the pandemic after the interim result of trials showed 90 per cent effectiveness, but questions remain about safety, distribution and its precise effect on the virus.
Before the vaccine is approved for use by health authorities around the world, it will have to meet certain safety requirements that vary by jurisdiction.
In the United States, the Food and Drug Administration is requiring manufacturers to produce safety data on half of subjects for two months after their second dose of the vaccine before it can be approved for emergency use.
Pfizer has said it expects to reach this by the third week of November, and has reported no serious adverse reactions in the nearly 40,000 trial participants who have received two doses of the vaccine.
The US multinational believes it can produce 50 million vaccine doses this year and up to 1.3 billion doses in 2021.